Fig. 1: Correlation between body mass index (BMI) and administered dose of lymphodepletion chemotherapy and impacts of BMI on clinical outcomes. | Blood Cancer Journal

Fig. 1: Correlation between body mass index (BMI) and administered dose of lymphodepletion chemotherapy and impacts of BMI on clinical outcomes.

From: The impact of obesity and body weight on the outcome of patients with relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel

Fig. 1

A Distribution of total delivered cyclophosphamide per body surface area and body mass index of 78 patients treated with axicabtagene ciloleucel. B Distribution of total delivered fludarabine per body surface area and body mass index of 78 patients treated with axicabtagene ciloleucel. C Event Free Survival after axicabtagene ciloleucel as stratified by obesity status. D Overall Survival after axicabtagene ciloleucel as stratified by obesity status. E Cumulative incidence of relapse after CAR T cell therapy as stratified by obesity status. F Cumulative incidence of non-relapse mortality as stratified by obesity status. G Cumulative incidence of CRS after axicabtagene ciloleucel as stratified by obesity status. H Cumulative incidence of ICANS after axicabtagene ciloleucel as stratified by obesity status.

Back to article page